Eliem Therapeutics is a clinical-stage biotechnology company focused on developing therapies for neuronal excitability disorders to address unmet needs in chronic pain, psychiatry, epilepsy and other disorders of the peripheral and central nervous systems. Co. is developing a pipeline of clinically differentiated product candidates focused on validated mechanisms of action with therapeutic potential to deliver therapeutics for patients with these disorders. Co.'s two clinical-stage candidates are ETX-810 and ETX-155. ETX-810 is a palmitoylethanolamide prodrug for the treatment of diabetic peripheral neuropathic pain and lumbosacral radicular pain, commonly referred to as sciatica. We show 9 historical shares outstanding datapoints in our ELYM shares outstanding history coverage, used to compute ELYM market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing ELYM market cap history over the course of time is important for investors
interested in comparing ELYM's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of ELYM versus a peer is one thing; comparing
ELYM market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like ELYM can fluctuate over the course of history.
With this page we aim to empower investors researching ELYM by allowing them to research the ELYM market cap history. |
Free ELYM Email Alerts:
Video: The Importance of Market Cap
